MYC and diffuse large B-cell lymphoma: To gain insight into changes in MYC, BCL-2, and BCL-6 expression levels in response to BET inhibitors, WT-MYC (U2932), SH (Raji), DHL (LY1, DHL2), and THL (VAL) expressing human DLBCL lines were treated with various doses of I-BET, JQ1, or OTX.